| Title |
EP300 Selectively Controls the Enhancer Landscape of MYCN-Amplified NeuroblastomaEP300 Controls Enhancers and MYCN in Neuroblastoma
|
|---|---|
| Published in |
Cancer Discovery, March 2022
|
| DOI | 10.1158/2159-8290.cd-21-0385 |
| Pubmed ID | |
| Authors |
Adam D. Durbin, Tingjian Wang, Virangika K. Wimalasena, Mark W. Zimmerman, Deyao Li, Neekesh V. Dharia, Luca Mariani, Noha A.M. Shendy, Stephanie Nance, Anand G. Patel, Ying Shao, Maya Mundada, Lily Maxham, Paul M.C. Park, Logan H. Sigua, Ken Morita, Amy Saur Conway, Amanda L. Robichaud, Antonio R. Perez-Atayde, Melissa J. Bikowitz, Taylor R. Quinn, Olaf Wiest, John Easton, Ernst Schönbrunn, Martha L. Bulyk, Brian J. Abraham, Kimberly Stegmaier, A. Thomas Look, Jun Qi |
X Demographics
The data shown below were collected from the profiles of 90 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 43 | 48% |
| United Kingdom | 3 | 3% |
| Germany | 2 | 2% |
| China | 2 | 2% |
| Australia | 1 | 1% |
| Austria | 1 | 1% |
| Hong Kong | 1 | 1% |
| Belgium | 1 | 1% |
| Ireland | 1 | 1% |
| Other | 3 | 3% |
| Unknown | 32 | 36% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 46 | 51% |
| Scientists | 33 | 37% |
| Practitioners (doctors, other healthcare professionals) | 6 | 7% |
| Science communicators (journalists, bloggers, editors) | 5 | 6% |
Mendeley readers
The data shown below were compiled from readership statistics for 96 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 96 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 15 | 16% |
| Researcher | 12 | 13% |
| Student > Bachelor | 11 | 11% |
| Student > Postgraduate | 8 | 8% |
| Student > Doctoral Student | 3 | 3% |
| Other | 6 | 6% |
| Unknown | 41 | 43% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 22 | 23% |
| Chemistry | 7 | 7% |
| Medicine and Dentistry | 7 | 7% |
| Agricultural and Biological Sciences | 7 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 3% |
| Other | 8 | 8% |
| Unknown | 42 | 44% |
Attention Score in Context
This research output has an Altmetric Attention Score of 66. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 May 2023.
All research outputs
#654,494
of 25,714,183 outputs
Outputs from Cancer Discovery
#352
of 4,148 outputs
Outputs of similar age
#17,190
of 448,820 outputs
Outputs of similar age from Cancer Discovery
#18
of 131 outputs
Altmetric has tracked 25,714,183 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,148 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 22.2. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 448,820 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 131 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 86% of its contemporaries.